Microarray‑based DNA methylation study of Ewing's sarcoma of the bone

Park,Hye‑Rim; Jung,Woon‑Won; Kim,Hyun‑Sook; Park,Yong‑Koo

doi:10.3892/ol.2014.2322

Microarray‑based DNA methylation study of Ewing's sarcoma of the bone

Authors:
- Hye‑Rim Park
- Woon‑Won Jung
- Hyun‑Sook Kim
- Yong‑Koo Park
View Affiliations

Affiliations: Department of Pathology, College of Medicine, Hallym University, Anyang, Gyeonggi 431‑070, Republic of Korea, Department of Biomedical Laboratory Science, College of Health Science, Cheongju University, Cheongju, Chungbuk 360-764, Republic of Korea, Department of Biomedical Laboratory Science, College of Health Science, Korea University, Seoul 136‑703, Republic of Korea, Department of Pathology, College of Medicine, Kyung Hee University, Seoul 130‑702, Republic of Korea
Published online on: July 7, 2014 https://doi.org/10.3892/ol.2014.2322
Pages: 1613-1617

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Alterations in DNA methylation patterns are a hallmark of malignancy. However, the majority of epigenetic studies of Ewing's sarcoma have focused on the analysis of only a few candidate genes. Comprehensive studies are thus lacking and are required. The aim of the present study was to identify novel methylation markers in Ewing's sarcoma using microarray analysis. The current study reports the microarray‑based DNA methylation study of 1,505 CpG sites of 807 cancer‑related genes from 69 Ewing's sarcoma samples. The Illumina GoldenGate Methylation Cancer Panel I microarray was used, and with the appropriate controls (n=14), a total of 92 hypermethylated genes were identified in the Ewing's sarcoma samples. The majority of the hypermethylated genes were associated with cell adhesion, cell regulation, development and signal transduction. The overall methylation mean values were compared between patients who survived and those that did not. The overall methylation mean was significantly higher in the patients who did not survive (0.25±0.03) than in those who did (0.22±0.05) (P=0.0322). However, the overall methylation mean was not found to significantly correlate with age, gender or tumor location. GDF10, OSM, APC and HOXA11 were the most significant differentially‑methylated genes, however, their methylation levels were not found to significantly correlate with the survival rate. The DNA methylation profile of Ewing's sarcoma was characterized and 92 genes that were significantly hypermethylated were detected. A trend towards a more aggressive behavior was identified in the methylated group. The results of this study indicated that methylation may be significant in the development of Ewing's sarcoma.

View Figures

View References

1	Esteller M: Epigenetics in cancer. N Engl J Med. 358:1148–1159. 2008.
2	Kang GH: CpG island hypermethylation in gastric carcinoma and its premalignant lesions. Korean J Pathol. 46:1–9. 2012.
3	Esteller M, Com PG, Baylin SB and Herman JG: A gene hypermethylation profile of human cancer. Cancer Res. 61:3225–3229. 2001.
4	Suzuki H, Watkins DN, Jair KW, et al: Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat Genet. 36:417–422. 2004.
5	Ushijima T: Detection and interpretation of altered methylation patterns in cancer cells. Nat Rev Cancer. 5:223–231. 2005.
6	Tsuchiya T, Sekine K, Hinohara S, Namiki T, Nobori T and Kaneko Y: Analysis of the p16INK4, p14ARF, p15, TP53, and MDM2 genes and their prognostic implications in osteosarcoma and Ewing sarcoma. Cancer Genet Cytogenet. 120:91–98. 2000.
7	Hoque MO, Kim MS, Ostrow KL, et al: Genome-wide promoter analysis uncovers portions of the cancer methylome. Cancer Res. 68:2661–2670. 2008.
8	Bibikova M, Lin Z, Zhou L, et al: High-throughput DNA methylation profiling using universal bead arrays. Genome Res. 16:383–393. 2006.
9	Lin Z, Thomas NJ, Bibikova M, et al: DNA methylation markers of surfactant proteins in lung cancer. Int J Oncol. 31:181–191. 2007.
10	Bibikova M, Chudin E, Wu B, et al: Human embryonic stem cells have a unique epigenetic signature. Genome Res. 16:1075–1083. 2006.
11	Bjornsson HT, Brown LJ, Fallin MD, et al: Epigenetic specificity of loss of imprinting of the IGF2 gene in Wilms tumors. J Natl Cancer Inst. 99:1270–1273. 2007.
12	de Alvia E, Lessnick SL and Sorensen PH: Ewing sarcoma. WHO Classification of Tumors of Soft Tissue and Bone. Fletcher CDM, Bridge JA, Hogendoorn PCW and Mertens F: IARC Press; Lyon: pp. 305–310. 2013
13	Kim GY, Park JH, Kim YW, Jung WW, Unni KK and Park YK: Absence of amplification of HER-2/neu (c-erbB-2) gene in Ewing’s sarcoma: a real-time polymerase chain reaction method. Pathol Res Pract. 200:663–667. 2004.
14	Farrand K, Jovanovic L, Delahunt B, et al: Loss of heterozygosity studies revisited: prior quantification of the amplifiable DNA content of archival samples improves efficiency and reliability. J Mol Diagn. 4:150–158. 2002.
15	Bibikova M and Fan JB: GoldenGate assay for DNA methylation profiling. Methods Mol Biol. 507:149–163. 2009.
16	Khoury JD: Ewing sarcoma family of tumors. Adv Anat Pathol. 12:212–220. 2005.
17	Fulda S, Küfer MU, Meyer E, van Valen F, Dockhorn-Dworniczak B and Debatin KM: Sensitization for death receptor- or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer. Oncogene. 20:5865–5877. 2001.
18	López-Guerrero JA, Pellín A, Noguera R, Carda C and Llombart-Bosch A: Molecular analysis of the 9p21 locus and p53 genes in Ewing family tumors. Lab Invest. 81:803–814. 2001.
19	Rathi A, Virmani AK, Harada K, et al: Aberrant hypermethylation of the HIC1 promoter is a frequent event in specific pediatric neoplasms. Clin Cancer Res. 9:3674–3678. 2003.
20	Martín-Subero JI, Kreuz M, Bibikova M, et al; Molecular Mechanisms in Malignant Lymphomas Network Project of the Deutsche Krebshilfe. New insights into the biology and origin of mature aggressive B-cell lymphomas by combined epigenomic, genomic, and transcriptional profiling. Blood. 113:2488–2497. 2009.
21	Serao NV, Delfino KR, Southey BR, Beever JE and Rodriguez-Zas SL: Cell cycle and aging, morphogenesis, and response to stimuli genes are individualized biomarkers of glioblastoma progression and survival. BMC Med Genomics. 4:492011.
22	Giovannini M, Selleri L, Hermanson GG and Evans GA: Localization of the human oncostatin M gene (OSM) to chromosome 22q12, distal to the Ewing’s sarcoma breakpoint. Cytogenet Cell Genet. 62:32–34. 1993.
23	Weiss TW, Simak R, Kaun C, et al: Oncostatin M and IL-6 induce u-PA and VEGF in prostate cancer cells and correlate in vivo. Anticancer Res. 31:3273–3278. 2011.
24	Ignatov A, Bischoff J, Ignatov T, et al: APC promoter hypermethylation is an early event in endometrial tumorigenesis. Cancer Sci. 101:321–327. 2010.
25	Shu Y, Wang B, Wang J, Wang JM and Zou SQ: Identification of methylation profile of HOX genes in extrahepatic cholangiocarcinoma. World J Gastroenterol. 17:3407–3419. 2011.
26	Fiegl H, Windbichler G, Mueller-Holzner E, et al: HOXA11 DNA methylation - a novel prognostic biomarker in ovarian cancer. Int J Cancer. 123:725–729. 2008.
27	Avigad S, Shukla S, Naumov I, et al: Aberrant methylation and reduced expression of RASSF1A in Ewing sarcoma. Pediatr Blood Cancer. 53:1023–1028. 2009.
28	Harada K, Toyooka S, Maitra A, et al: Aberrant promoter hypermethylation and silencing of the RASSF1A gene in pediatric tumors and cell lines. Oncogene. 21:4345–4349. 2002.
29	Garcia-Manero G: Demethylating agents in myeloid malignancies. Curr Opin Oncol. 20:705–710. 2008.